Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials

ClinicalLIVEUpdated 18 Nov 2026

New Clinical Trials

Clinical trials companies registered in the last 30 days, worldwide, with the sponsor, phase and countries.

Sources: ClinicalTrials.gov · Rebuilt weekly · Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase.

Trials
777
in the 30 days to 2026-11-18
Added in 30 days
777
to 18 Nov 2026
Top country
United States
192 · 25% of the list
Phase covered
8
distinct values
Snapshot · 18 Nov 2026
Explore all 777

Signals

What the register says this week, and why it matters if you sell into it.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
  3. 174 of the listed studies are device, diagnostic or digital-health studies (no drug phase).
  4. A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

Export the full new clinical trials

777 rows as a .csv. Free. Every field, with its source link.

Country
Phase 1
Study type
208 / 777 trials
PostedSponsorStudyPhaseStatus
12 Nov 2026Beijing VDJBio Co., LTD.ChinaPhase I Trial of Subcutaneous VDJ010 In Healthy Subjects and Patients With Ulcerative ColitisPhase 1Recruiting12 Nov 2026BeOne MedicinesA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of BON-107 in Healthy ParticipantsPhase 1Not Yet Recruiting12 Nov 2026Hangzhou DAC Biotechnology Co., Ltd.ChinaA Study of DXC016 in Patients With Advanced Solid Tumors.Phase 1Not Yet Recruiting12 Nov 2026InSilico Medicine Hong Kong LimitedUnited Arab EmiratesA Phase 1, Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISM9528Phase 1Recruiting12 Nov 2026Jiangsu Hansoh Pharmaceutical Co., Ltd.ChinaA Phase I Study to Evaluate the Effect of Food on the Pharmacokinetics of HS-10382 Tablets in Healthy ParticipantsPhase 1Not Yet Recruiting12 Nov 2026Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyGermanyStudy of Multiple Ascending Doses (MAD) of M5542 in Participants With Moderate and Severe EczemaPhase 1Not Yet Recruiting12 Nov 2026Neurocrine BiosciencesUnited StatesStudy of NBIB-223 Gene Therapy in Friedreich's Ataxia (FACET)Phase 1Not Yet Recruiting12 Nov 2026PfizerA Study to Learn How Different Amounts of the Study Medicine Called PF-08166744 Are Tolerated and Act in Healthy Adults.Phase 1Not Yet Recruiting12 Nov 2026PfizerUnited StatesA Study to Learn About the Study Medicine Called Prifetrastat in People With Renal ImpairmentPhase 1Not Yet Recruiting12 Nov 2026Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.ChinaA Phase I of FXS0260 in Advanced Solid TumorPhase 1Not Yet Recruiting12 Nov 2026Suzhou Ribo Life Science Co. Ltd.Phase I Trial of RBD4059 in Chinese Healthy ParticipantsPhase 1Not Yet Recruiting12 Nov 2026Whanin Pharmaceutical CompanyA Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of WIF-2402 in Healthy AdultsPhase 1Not Yet Recruiting12 Nov 2026YGION Biomedical GmbHAustriaFirst Study Evaluating the Safety and Dosage of YG-01 in Patients With GlioblastomaPhase 1Not Yet Recruiting10 Nov 2026Beijing Inno Medicine Co., Ltd.United States, ChinaA Phase I Clinical Study of YN003 in the Treatment of GliomaPhase 1Recruiting10 Nov 2026Eli Lilly and CompanyUnited StatesA Study of LY3981314 in Participants With Autoimmune HepatitisPhase 1Not Yet Recruiting10 Nov 2026Eli Lilly and CompanyUnited States, France, JapanA Study of LY4336619 in Adult Participants With Advanced Solid TumorsPhase 1Not Yet Recruiting10 Nov 2026Kura Oncology, Inc.Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDSPhase 1Not Yet Recruiting10 Nov 2026MipSalus ApsDenmarkA First-in-Human Study of Phelimin in Healthy Volunteers and Adults With PKUPhase 1Not Yet Recruiting10 Nov 2026Stealth BioTherapeutics Inc.Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Subcutaneous Injections of Elamipretide in Pediatric Subjects With Barth SyndromePhase 1Not Yet Recruiting10 Nov 2026Vigonvita Life SciencesChinaStudy of Food Effects of VV261 Tablets in Healthy Trial ParticipantsPhase 1Not Yet Recruiting10 Nov 2026Xiamen Amoytop Biotech Co., Ltd.ChinaACT201 Injection in Participants With Chronic Hepatitis B (CHB) on Nucleos(t)Ide Analog Therapy - Phase IbPhase 1Not Yet Recruiting9 Nov 2026AbbVieUnited StatesA Study to Assess How Intravenous and Subcutaneous Administrations of Trosunilimab Move Through the Body of Healthy Adult ParticipantsPhase 1Recruiting9 Nov 2026Boehringer IngelheimUnited States, Australia, JapanA Study of BI 4015092, Alone or in Combination With Other Cancer Treatment, in Patients With Advanced Cancer That Has a KRAS G12D MutationPhase 1Not Yet Recruiting9 Nov 2026Clement Therapeutics, Inc.CMT-133 in Healthy Adult ParticipantsPhase 1Not Yet Recruiting9 Nov 2026CSPC Megalith Biopharmaceutical Co.,Ltd.Immunogenicity and Safety of SYS6057 in the Participants Aged 18 Years and AbovePhase 1Not Yet Recruiting9 Nov 2026EktaHTunisiaA Single Ascending Dose and Multiple Ascending Dose Trial to Assess the Dose, the Efficacy and Oro-sensitivity of Two Modified Linoleic Acids NKS-3 and NKS-5Phase 1Completed9 Nov 2026Iongen Therapeutics Co., Ltd.New ZealandA Study to Assess IG001643 in Healthy ParticipantsPhase 1Not Yet Recruiting9 Nov 2026KaileraUnited StatesA Study to Investigate the Effect of Injection Site and Ethnicity on KAI-4729 Pharmacokinetics in Non-Asian and Asian Participants Living With Obesity or OverweightPhase 1Not Yet Recruiting9 Nov 2026Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and CompanyUnited StatesA Study of Tersolisib (LY4064809) in Participants With Kidney Impairment Compared With Participants With Normal Kidney FunctionPhase 1Not Yet Recruiting9 Nov 2026Triastek, lnc.ChinaA Pharmacokinetic Study of Budesonide Delayed Release Tablet D23A (D23) in Healthy Chinese Participants Under Fasting ConditionsPhase 1Active Not Recruiting6 Nov 2026AmgenComparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple DosesPhase 1Not Yet Recruiting6 Nov 2026Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.ChinaA Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid TumorsPhase 1Recruiting6 Nov 2026Chengdu SciMount Pharmatech Co., Ltd.ChinaA First-in-human Study of SMP-656 in Subjects With Locally Advanced/ Metastatic HER2 Expressing or Mutated Solid TumorsPhase 1Completed6 Nov 2026Gan & Lee Pharmaceuticals.ChinaA Phase I Study of GLR2053 Tablets in Chinese Healthy Adult ParticipantsPhase 1Not Yet Recruiting6 Nov 2026Haisco Pharmaceutical Group Co., Ltd.A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic DermatitisPhase 1Not Yet Recruiting6 Nov 2026Hexin (Suzhou) Pharmaceutical Technology Co., LtdChinaEvaluation of the I-phase Clinical Trial of 177Lu-HX02 Injection in Patients With Advanced Malignant Solid TumorsPhase 1Enrolling By Invitation6 Nov 2026Huabo Biopharm Co., Ltd.ChinaA Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous Injection in Low-Body-Weight Subjects; and Pharmacokinetics at Different Subcutaneous Injection Sites at the Same DosePhase 1Recruiting6 Nov 2026Merck Sharp & Dohme LLCA Clinical Trial of MK-6916 in Participants With Moderate and Severe Kidney Disease Compared to Healthy Controls (MK-6916-013)Phase 1Not Yet Recruiting6 Nov 2026Neurelis, Inc.Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult ParticipantsPhase 1Not Yet Recruiting6 Nov 2026Novartis PharmaceuticalsAn Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)Phase 1Not Yet Recruiting6 Nov 2026Personalized Stem Cells, Inc.United StatesPilot Safety and Exploratory Efficacy of PSC-05 for the Treatment of Chronic Mild Traumatic Brain InjuryPhase 1Enrolling By Invitation6 Nov 2026Rapport Therapeutics Inc.AustraliaStudy Designed to Evaluate the Safety, Tolerability, and PK of RAP-219 Formulated as an Long Acting Injectable.Phase 1Recruiting6 Nov 2026SanofiAn Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 SubstratesPhase 1Not Yet Recruiting6 Nov 2026Syndax PharmaceuticalsA Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal ImpairmentPhase 1Not Yet Recruiting6 Nov 2026Techpool Bio-Pharma Co., Ltd.ChinaPharmacokinetics, Safety and Tolerability of Single Sequential and Multiple Intravenous Infusions of Ulinastatin for Injection in Healthy Chinese ParticipantsPhase 1Not Yet Recruiting6 Nov 2026The United Bio-Technology (Hengqin) Co., Ltd.ChinaA Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of UBT48128 Tablets in Healthy ParticipantsPhase 1Not Yet Recruiting6 Nov 2026Zi Diligence BiocenterEgyptAn Open-label, Randomized, Single Oral Dose, Two-period, Two-sequence, Two-way, Crossover Bioequivalence Study on Healthy Adult Male Participants Under Fed Conditions to Compare, Test Product Palbociclib-EVAPHARMA 125 mg Hard Gelatin Capsule, Versus the Reference Product Ibrance™125 mg CapsulesPhase 1Completed5 Nov 2026Avata Biosciences Holdings LtdA Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered Cannabidiol Capsules (AVAT-121) and Epidyolex® in Healthy AdultsPhase 1Not Yet Recruiting5 Nov 2026DianosicSafety and Tolerability of Fluticasone Propionate 10% Nasal Insert in Participants With Chronic Allergic RhinitisPhase 1Not Yet Recruiting5 Nov 2026Eli Lilly and CompanyUnited StatesA Study of Imlunestrant (LY3484356) in Healthy Female ParticipantsPhase 1Not Yet Recruiting

// How AOS uses this

Every row here is a potential account. AOS finds the ones that need what you sell, maps the decision makers and prepares the outreach for your approval.